|
Friday, 23 April 2021, 9:07 JST | |
| | | | Source: Eisai | |
|
|
TOKYO, Apr 23, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that Biogen (Nasdaq: BIIB) has disclosed, in its Q1 2021 Earnings Press Release issued on April 22, its current submission status of the Marketing Authorization Applications (MAA) for aducanumab, an investigational treatment for Alzheimer's disease, in countries other than the United States, Japan, and in Europe which have been announced previously. In the first quarter of 2021 Biogen submitted a MAA to Ag?ncia Nacional de Vigil?ncia Sanit?ria (ANVISA) in Brazil for aducanumab an investigational treatment for Alzheimer's disease. This application is currently in queue for review. Biogen also submitted MAAs for aducanumab to Health Canada, the Therapeutic Goods Agency in Australia, and Swissmedic in Switzerland, all of which are subject to agency validation of whether the applications are accepted. Aducanumab is being jointly developed by Biogen and Eisai.
Media Inquiries: Public Relations Department, Eisai Co., Ltd. +81-(0)3-3817-5120
Topic: Press release summary
Source: Eisai
Sectors: BioTech
https://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
Eisai Related News |
|
Tuesday, 29 July 2025, 9:01 JST |
LENVIMA(R) (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma |
|
Friday, 25 July 2025, 13:31 JST |
Eisai Listed for 24th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment |
|
Wednesday, 23 July 2025, 10:07 JST |
Launch of Beova(R) Tablets in Thailand for Overactive Bladder |
|
Tuesday, 22 July 2025, 11:56 JST |
Eisai To Present Four-Year Efficacy And Safety Data On Continuous Treatment With Lecanemab At The Alzheimer's Association International Conference 2025 |
|
2025年7月16日 14時40分 JST |
エーザイ、抗アミロイドβ抗体レカネマブの創薬研究が「第 9 回バイオインダストリー大賞」を受賞 |
|
More news >> |
|
|
|